Skip to Main Content
Table 2—

Outcome measures using insulin detemir or NPH insulin as basal insulin therapy in type 1 diabetes

IDet12hIDetmorn+bedNPHP
HbA1c (%) 7.75 ± 0.07 7.78 ± 0.07 7.94 ± 0.07 0.082 
Clinic FPG (mmol/l) 9.75 ± 0.37 8.94 ± 0.37 11.24 ± 0.38 <0.001 
Self-monitored prebreakfast plasma glucose (mmol/l)     
 Mean 8.28 ± 0.20 8.26 ± 0.20 9.05 ± 0.21 0.005 
 Within-patient SD 2.95 (2.80–3.10) 2.91 (2.76–3.05) 3.49 (3.31–3.68) <0.001 
Body weight change (kg) 0.02 ± 0.22 0.24 ± 0.22 0.86 ± 0.23 0.018 
CGMS glucose profiles deviation from average (mmol/l · h)     
 >24 h 54.9 ± 2.95 63.7 ± 2.92 59.7 ± 2.92 0.092 
 Overnight 15.9 ± 0.98 17.7 ± 1.01 16.2 ± 1.00 NS 
Hypoglycemia in final 12 weeks     
 Minor     
  Anytime     
   n (%) 114 (84) 114 (83) 107 (84)  
   Events 842 780 1,074 0.020 
  Nocturnal     
   n (%) 59 (44) 47 (34) 64 (50)  
   Events 125 82 166 0.002 
 Major     
  Anytime     
   n (%) 6 (4) 11 (8) 10 (8)  
   Events 24 12 NS 
  Nocturnal     
   n (%) 3 (2) 5 (4) 4 (3)  
   Events NS 
Insulin dose (units/day)     
 Basal 36.7 ± 16.4 36.3 ± 16.5 34.8 ± 13.5 NS 
 Mealtime 27.9 ± 15.0 29.4 ± 12.2 29.4 ± 12.5 NS 
IDet12hIDetmorn+bedNPHP
HbA1c (%) 7.75 ± 0.07 7.78 ± 0.07 7.94 ± 0.07 0.082 
Clinic FPG (mmol/l) 9.75 ± 0.37 8.94 ± 0.37 11.24 ± 0.38 <0.001 
Self-monitored prebreakfast plasma glucose (mmol/l)     
 Mean 8.28 ± 0.20 8.26 ± 0.20 9.05 ± 0.21 0.005 
 Within-patient SD 2.95 (2.80–3.10) 2.91 (2.76–3.05) 3.49 (3.31–3.68) <0.001 
Body weight change (kg) 0.02 ± 0.22 0.24 ± 0.22 0.86 ± 0.23 0.018 
CGMS glucose profiles deviation from average (mmol/l · h)     
 >24 h 54.9 ± 2.95 63.7 ± 2.92 59.7 ± 2.92 0.092 
 Overnight 15.9 ± 0.98 17.7 ± 1.01 16.2 ± 1.00 NS 
Hypoglycemia in final 12 weeks     
 Minor     
  Anytime     
   n (%) 114 (84) 114 (83) 107 (84)  
   Events 842 780 1,074 0.020 
  Nocturnal     
   n (%) 59 (44) 47 (34) 64 (50)  
   Events 125 82 166 0.002 
 Major     
  Anytime     
   n (%) 6 (4) 11 (8) 10 (8)  
   Events 24 12 NS 
  Nocturnal     
   n (%) 3 (2) 5 (4) 4 (3)  
   Events NS 
Insulin dose (units/day)     
 Basal 36.7 ± 16.4 36.3 ± 16.5 34.8 ± 13.5 NS 
 Mealtime 27.9 ± 15.0 29.4 ± 12.2 29.4 ± 12.5 NS 

Data are means ± SE, estimate (95% CI) for within-patient SD, mean ± SD for insulin doses, or n (%). n = 130–132 for the IDet12h group, n = 131–135 for the IDetmorn+bed group, and n = 119–125 for the NPH group, except for GCMS, where n = 58–60 for 24 h and 62–69 for overnight. Differences and confidence intervals for pairs of treatments are given in Table 3. n for hypoglycemia is number of people having at least one episode. P value for ANOVA comparison of the three treatment groups together.

Close Modal

or Create an Account

Close Modal
Close Modal